Sakir Mutevelic, MD, Curium's Chief Medical Officer said: "The completion of enrollment of the SOLAR-RECUR trial is yet ...

Lilly has reported comprehensive outcomes from the Phase III trial of tirzepatide for individuals with heart failure with ...

Researchers from the National Institutes of Health (NIH) have developed an artificial intelligence (AI) algorithm to help speed up the process of matching potential volunteers to relevant clinical ...

A peptide hormone produced in the brain that triggers physiological reproductive responses has been 'hacked' by scientists to form an effective, safe and non-invasive way to treat chronic gut pain. It ...

The pathology and radiology giant is recovering from its post-pandemic malaise and says earnings should improve this year ...

Atrial fibrillation, or Afib, is the most common type of heart arrhythmia. Afib increases your risk of heart attack and ...

Levine Children's Hospital has several experimental treatments that help families get lifesaving care without having to leave ...

Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

A year ago, there was 1 drug for idiopathic pulmonary fibrosis in trials at Temple Health. Now there are 10 active trials and 8 more coming up.

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...